Fielder Capital Group LLC Has $423,000 Stock Position in AbbVie Inc. (NYSE:ABBV)

Fielder Capital Group LLC grew its holdings in AbbVie Inc. (NYSE:ABBV) by 5.0% in the fourth quarter, HoldingsChannel reports. The fund owned 2,382 shares of the company’s stock after buying an additional 113 shares during the period. Fielder Capital Group LLC’s holdings in AbbVie were worth $423,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. Parkside Financial Bank & Trust grew its position in shares of AbbVie by 2.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 17,313 shares of the company’s stock worth $3,077,000 after purchasing an additional 394 shares in the last quarter. Sentinel Trust Co. LBA grew its position in AbbVie by 3.9% during the fourth quarter. Sentinel Trust Co. LBA now owns 16,144 shares of the company’s stock worth $2,869,000 after buying an additional 601 shares in the last quarter. Wakefield Asset Management LLLP increased its stake in AbbVie by 0.6% during the 4th quarter. Wakefield Asset Management LLLP now owns 11,405 shares of the company’s stock worth $2,027,000 after acquiring an additional 65 shares during the period. Fort Sheridan Advisors LLC raised its holdings in AbbVie by 2.0% in the 4th quarter. Fort Sheridan Advisors LLC now owns 66,490 shares of the company’s stock valued at $11,815,000 after acquiring an additional 1,307 shares in the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its position in shares of AbbVie by 88.0% during the 4th quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 940 shares of the company’s stock valued at $167,000 after acquiring an additional 440 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ABBV shares. Morgan Stanley boosted their price target on AbbVie from $224.00 to $239.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Piper Sandler upped their price target on shares of AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. Citigroup lifted their price objective on shares of AbbVie from $205.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Leerink Partnrs upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, Wells Fargo & Company lifted their price target on AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $208.35.

AbbVie Price Performance

AbbVie stock opened at $205.06 on Friday. The firm has a market cap of $362.00 billion, a P/E ratio of 85.44, a P/E/G ratio of 1.62 and a beta of 0.58. The stock’s 50 day moving average is $183.75 and its 200 day moving average is $186.85. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.55. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter last year, the company posted $2.79 earnings per share. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.20%. AbbVie’s payout ratio is 273.33%.

Insider Buying and Selling

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now owns 6,983 shares of the company’s stock, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Perry C. Siatis sold 5,778 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the sale, the executive vice president now owns 22,381 shares of the company’s stock, valued at approximately $4,429,199.90. This represents a 20.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.